Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
2024 · Diagnostic Pathology · 17 citations
https://doi.org/10.1186/s13000-024-01557-3
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
27
Papers
249
Citations
9
h-index
9
i10-index
Lixia Chen is an academic researcher from Shenyang Pharmaceutical University. The author has contributed to research in topics: Nanoplatforms for cancer theranostics & Pharmacological Effects of Natural Compounds & Nanoparticle-Based Drug Delivery. The author has an h-index of 9, co-authored 23 publications.
ORCID: 0000-0002-5010-5818https://doi.org/10.1186/s13000-024-01557-3
https://doi.org/10.2174/1389200224666230202144113
Click to start Chat